Financing led by Casdin Capital, Sofinnova Partners – initial seed investor, and an undisclosed investor Mnemo delivers epigenetic antigens, stronger T cells and best-in-class manufacturing established with groundbreaking research from Institut Curie and Memorial Sloan Kettering PARIS, June 16, 2021 /PRNewswire/ — Mnemo Therapeutics, a biotechnology company developing powerful cell therapies using a novel target identification engine, stronger T cells and best-in-class manufacturing, today… Source link
Read More »Mnemo Therapeutics Announces €75 million Series A to Accelerate Next Generation Integrated CAR-T and Epigenetic Targeting Platform
